Sangamo said it plans to explore all options to commercialise the asset, including seeking a potential new collaboration partner.

Global rare disease company Immedica Pharma has agreed to acquire Marinus Pharmaceuticals for an enterprise value of approximately $151m.

NVP-1805R2 is under clinical development by NVP Healthcare and currently in Phase I for Unspecified Cardiovascular Disorders.

Xaluritamig is under clinical development by Amgen and currently in Phase I for Prostate Cancer. According to GlobalData, Phase I drugs for Prostate Cancer have a 76% phase transition success rate ...

APG-157 is under clinical development by Aveta Biomics and currently in Phase II for Recurrent Glioblastoma Multiforme (GBM).

Rifaximin is under clinical development by Nexpharm Korea and currently in Phase I for Irritable Bowel Syndrome.

LXE-408 is under clinical development by Novartis and currently in Phase I for Chagas Disease (American Trypanosomiasis).

TAS-0728 is under clinical development by Taiho Pharmaceutical and currently in Phase II for Endometrial Cancer.

CT-7439 is under development for the treatment of solid tumors including breast cancer, ovarian cancer and Ewing's Sarcoma. It acts by targeting cyclin dependent kinase 12 and 13 (CDK12 and 13). It is ...

Linavonkibart is under clinical development by Scholar Rock and currently in Phase I for Nasopharyngeal Cancer.

Tevimbra is under clinical development by BeiGene and currently in Phase II for Muscle Invasive Bladder Cancer (MIBC).

PTS-500 is under clinical development by Gongwin Biopharm and currently in Phase II for Non-Small Cell Lung Cancer.